This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by educational grants from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Merck & Co., Inc., Novo Nordisk Inc., and Novartis Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on November 15, 2022 and is valid until November 15, 2023. Requests for credit must be made no later than November 15, 2023.

TARGET AUDIENCE

The primary target audiences for the HCP activity are Cardiologists, primary care physicians, nurse practitioners, and physicians

STATEMENT OF NEED/PROGRAM OVERVIEW

Despite advances in heart failure (HF) treatment over the past decade, the disease is still associated with high costs and high rates of morbidity, hospitalization, and mortality. In 2021, an update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure was published and yet the treatment course remains confusing for many clinicians. Research is also rapidly emerging on novel therapies for both HF with preserved ejection fraction (HFpEF) and HF with reduced ejection fraction (HFrEF), including anti-diabetic agents that have shown cardiovascular benefits.

In this program a panel of expert cardiologists will navigate these guideline-concordant treatment approaches to promote effective care of HF and optimization of pharmacotherapy. Panelists will review the latest updates to the treatment guidelines and the rationales for those changes, along with clinical trial data related to HFpEF and HFrEF. Clinicians will be prepared to address barriers to guideline-directed medical therapy in effort to reduce mortality rates and improve quality of life for their patients with HF.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Explain the rationale for important changes in the 2022 AHA/ACC/HFSA guideline for the management of heart failure
• Identify HF patients who should receive ARNI/ACE/ARB as first line treatment, and those who should receive a SGLT2 inhibitors as part as therapy intensification newer HF agents with efficacy in reducing mortality and hospitalization rates in patients with HF
• Describe the mechanisms of action of newly approved agents for the management of HF and how they relate to HF pathophysiology (ARNI and SGLT2 inhibitors)
• Discuss recent clinical trial data from emerging agents that have demonstrated efficacy in the treatment of HFrEF and HFpEF

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC President-American Society for Preventive Cardiology Director, Preventive Cardiology Associate Director, Barbra Streisand Women’s Heart Center Associate Director, Preventive and Cardiac Rehabilitation Center Anita Dann Friedman Endowed Chair in Women’s Cardiovascular Medicine & Research Smidt Heart Institute	Nothing to disclose
Scott Soloman, MD Edward D. Frohlich Distinguished Chair, Professor of Medicine Harvard Medical School Director of Clinical Trials Outcomes Center and the Cardiac Imaging Core Laboratory Brigham and Women’s Hospital	Consulting Fee (e.g., Advisory Board): Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boeringer-Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProThera, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, Puretech Health Contracted Research: Actelion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesoblast, MyoKardia, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, US2.AI
Gregg Fonarow, MD Eliot Corday Professor of Cardiovascular Medicine and Science Director, Ahmanson-UCLA Cardiomyopathy Center Co-Director, UCLA Preventative Cardiology Program Chief, UCLA Division of Cardiology (Interim) David Geffen School of Medicine, UCLA	Consulting Fee: Abbott, Amgen, AstraZeneca, Cytokinetics Egnite, Janssen, Medtronic, Merck Novartis, Pfizer, Urovant, Research: NIH Speakers Bureau: Novartis

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Lauren Sinclair	Nothing to disclose
Carole Drexel	Nothing to disclose
Colleen Hefner	Nothing to disclose
Caroline Laurendeau	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com .

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Society for Preventive Cardiology (ASPC).

ACKNOWLEDGEMENT

This activity is supported by educational grants from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, Merck Sharp & Dohme Corp, and Novo Nordisk Inc.

DATE OF RELEASE/EXPIRATION

This activity was released on June 21, 2022 and is valid for 12 months. Requests for credit must be made no later than June 21, 2023.

TARGET AUDIENCE

The primary target audiences for the HCP activity are cardiologists and specialty NPs and PAs. The secondary target audiences are endocrinologists and primary care clinicians.

STATEMENT OF NEED/PROGRAM OVERVIEW

Of the 415 million people living with diabetes in the world, 90% have type 2 diabetes (T2D), which doubles the risk of major cardiovascular complications. Cardiovascular disease remains the major cause of increased mortality in this patient population.

Initially investigated as glucose-lowering therapies, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have since demonstrated cardiac benefits and are becoming an important part of the cardiologist's armamentarium. Cardiologists are now faced with the challenge of identifying patients who best qualify for this therapeutic approach and selecting treatment in a patient-centric manner. However, a lack of familiarity with these agents may make cardiology clinicians hesitant to integrate these therapies into practice.

Join an esteemed panel of cardiology experts to evaluate the different GLP-1 RA formulations and explore how they differ in terms of documented cardiovascular impacts and weight reduction. Panelists will review the latest guideline recommendations on the management of CV risk in people with T2D and discuss the proper use of GLP-1 RAs in practice, including patient selection.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Differentiate the various GLP-1 RAs based on their documented impact on CV-related markers and weight reduction in addition to their glucose lowering properties
• Apply guideline-based recommendations regarding the use of GLP-1 RA therapy in patients with T2D

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC President-American Society for Preventive Cardiology Director, Preventive Cardiology Associate Director, Barbra Streisand Women’s Heart Center Associate Director, Preventive and Cardiac Rehabilitation Center Smidt Heart Institute	Nothing to disclose
Keith C. Ferdinand , MD, FACC, FAHA, FASPC, FNLA Gerald S. Berenson Endowed Chair in Preventive Cardiology Professor of Medicine Tulane University School of Medicine	Consulting Fee (e.g., Advisory Board): Amgen, Sanofi, Boehringer Ingelheim, Novartis, Quantum Genomics, Eli Lilly
Darren McGuire, MD, MHSc Dallas Heart Ball Chair for Research on Heart Disease in Women University of Texas Southwestern Medical Center	Consulting Fee (e.g., Advisory Board): Lilly USA, Boehringer Ingelheim, Merck & Co, Novo Nordisk, Applied Therapeutics, Metavant, Sanofi, Afimmune, CSL Behring, Bayer, GlaxoSmithKline Honoraria: Boehringer Ingelheim, Sanofi, Merck & Co, Pfizer, AstraZeneca, Novo Nordisk, Esperion, Lilly USA, Lexicon, CSL Behring

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Carole Drexel	Nothing to disclose
Colleen Hefner	Nothing to disclose
Caroline Laurendeau	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com

Technical Support:

For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Support@CardioCareLive.com .

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Society for Preventive Cardiology (ASPC).

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, and Merck Sharp & Dohme Corp.

DATE OF RELEASE/EXPIRATION

This activity was released on February 9, 2022 and is valid until February 9, 2023. Requests for credit must be made no later than February 9, 2023

TARGET AUDIENCE

Cardiologists, internal medicine physicians, primary care physicians, clinical pharmacists, nurse practitioners, physician assistants, nurses, and other clinicians who care for patients with heart failure.

STATEMENT OF NEED/PROGRAM OVERVIEW

Anticoagulant therapy is an essential part of managing many cardiovascular diseases. The last decade has seen an expansion of therapies aimed at managing patients with multiple underlying CV manifestations, including the advent of direct oral anticoagulants (DOACs), which changed the standard of care.

Ultimately, the choice of anticoagulant therapy must be considered in the context of underlying CV disease, as well as complex comorbidities (i.e., renal disease, obesity). As the rapid evolution of evidence‐based practice parallels more widespread use of novel oral anticoagulants, it is imperative that clinicians remain up to date on optimal anticoagulation strategies in CV.

Join an esteemed panel of expert clinicians to review the evidence-based recommendations for use of DOACs in patients with cardiovascular disease, including the management of a major and minor bleeding events. The expert panelists will also evaluate the Pharmacoeconomics of current DOAC reversal strategies and the long-term implications for patient morbidity and mortality.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Summarize data around emerging indications for DOACs
• Adopt the 2020 ACC Expert Consensus Decision Pathway on Management of Bleeding in Patients on Direct Oral Anticoagulants
• Evaluate long-term impacts on patient morbidity and mortality and cost effectiveness with specific DOAC reversal agent’s vs usual care with 4F-PCC or aPCC in the critical-care setting

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Name of Faculty or Presenter	Reported Financial Relationship
Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC President-American Society for Preventive Cardiology Director, Preventive Cardiology Associate Director, Barbra Streisand Women’s Heart Center Associate Director, Preventive and Cardiac Rehabilitation Center Smidt Heart Institute	Nothing to disclose
Deepak L. Bhatt, MD, MPH Executive Director of Interventional Cardiovascular Programs Brigham and Women's Hospital Heart and Vascular Center Professor of Medicine, Harvard Medical School	Contracted Research: Abbott, Afimmune, Aker Biomarine, Amarin, Amgen, AstraZeneca, Bayer, Beren, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, CellProthera, Cereno Scientific, Chiesi, CSL Behring, Eisai, Ethicon, Faraday Pharmaceuticals, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Garmin, HLS Therapeutics, Idorsia, Ironwood, Ischemix, Janssen, Javelin, Lexicon, Lilly, Medtronic, Moderna, MyoKardia, NirvaMed, Novartis, Novo Nordisk, Owkin, Pfizer, PhaseBio, PLx Pharma,Recardio, Regeneron, Roche, Sanofi, Stasys, Synaptic, The Medicines Company, 89Bio
Ty Gluckman, MD, MHA,FAAC, FAHA Medical Director Center for Cardiovascular Analytics, Research, and Data Science (CARDS) Providence Heart Institute Providence St. Joseph Health	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Carole Drexel	Nothing to disclose
Eve Wilson	Nothing to disclose
Caroline Laurendeau	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION

Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Technical Support:
For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Info@CardioCareLive.com.

This activity is jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with the American Society for Preventive Cardiology (ASPC) and the Association of Black Cardiologists.

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Alexion Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC, and Merck Sharp & Dohme Corp.

DATE OF RELEASE/EXPIRATION

This activity was released on January 5, 2022 and is valid until January 5, 2023. Requests for credit must be made no later than January 5, 2023.

TARGET AUDIENCE

Cardiologists, internal medicine physicians, primary care physicians, clinical pharmacists, nurse practitioners, physician assistants, nurses, and other clinicians who care for patients with heart failure.

STATEMENT OF NEED/PROGRAM OVERVIEW

Anticoagulant therapy is an essential part of managing many cardiovascular diseases. The last decade has seen an expansion of therapies aimed at managing patients with multiple underlying CV manifestations, including the advent of direct oral anticoagulants (DOACs), which changed the standard of care. Ultimately, the choice of anticoagulant therapy must be considered in the context of underlying CV disease, as well as complex comorbidities (i.e., renal disease, obesity). As the rapid evolution of evidence‐based practice parallels more widespread use of novel oral anticoagulants, it is imperative that clinicians remain up to date on optimal anticoagulation strategies in CV. Join an esteemed panel of expert clinicians to review the evidence-based recommendations for use of DOACs in patients with cardiovascular disease, including the management of a major and minor bleeding events. The expert panelists will also evaluate the Pharmacoeconomics of current DOAC reversal strategies and the long-term implications for patient morbidity and mortality.

EDUCATIONAL OBJECTIVES

After completing this activity, the participant should be better able to:

• Identify patient-centric risk factors for development and progression of HF in a racially diverse patient population
• Review best-practice recommendations for pharmacological management of HF, with a focus on African American patients
• Discuss safety, efficacy, and clinical-outcomes data related to new and emerging therapies for HF

PHYSICIAN ACCREDITATION STATEMENT

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

PHYSICIAN CREDIT DESIGNATION

Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ESTIMATED TIME TO COMPLETE

This activity should take approximately 60 minutes to complete.

INSTRUCTIONS TO RECEIVE CREDIT

In order to receive credit for this activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated. The faculty have the following relevant financial relationships with ineligible companies:  

Name of Faculty or Presenter	Reported Financial Relationship
Martha Gulati MD, MS, FACC, FAHA, FASPC, FESC President-American Society for Preventive Cardiology Director, Preventive Cardiology Associate Director, Barbra Streisand Women’s Heart Center Associate Director, Preventive and Cardiac Rehabilitation Center Smidt Heart Institute	Nothing to disclose
Nasrien Ibrahim Assistant Program Director, Cardiology Fellowship Director, Heart Failure Research Inova Heart and Vascular Institute	Consulting Fee (e.g., Advisory Board): Cytokinetics Honoraria: Novartis, Medtronic, Roche, Cytokinetics
Clyde Yancy Vice-Dean of Diversity & Inclusion and Professor and Chief of the Division of Cardiology at Northwestern University Feinberg School of Medicine	Nothing to disclose

The planners and managers have the following relevant financial relationships with ineligible companies:

Name of Planner or Manager	Reported Financial Relationship
Lindsay Borvansky	Nothing to disclose
Andrea Funk	Nothing to disclose
Liddy Knight	Nothing to disclose
Ashley Cann	Nothing to disclose
Kim Rodriguez	Nothing to disclose
Carole Drexel	Nothing to disclose
Eve Wilson	Nothing to disclose
Caroline Laurendeau	Nothing to disclose

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.  

CONTACT INFORMATION

Accreditation Support: For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com. Technical Support: For any technical issues or issues with your CME Certificate, please contact CardioCareLive at 877-394-1306 or at Info@CardioCareLive.com.